Publications

  • Biorelevant dissolution to differentiate formulation performance for inhalation  Beatriz Noriega (Hovione FarmaCiencia SA, Portugal /Med.ULisboa, Faculdade de Farmácia, Universidade de Lisboa) Maria Malmlöf, Per Gerde (Inhalation Sciences, Huddinge, Sweden / Institute of Environmental Medicine, Karolinska Institutet, Sweden) Mattias Nowenwik (ISAB) Luisa Corvo2 , Eunice Costa (Med.ULisboa, Faculdade de Farmácia, Universidade de Lisboa) Poster 58, DDL 2019 Conference, December 2019.

  • Adapting the Aerogen Mesh Nebulizer for Dried Aerosol Exposures Using the PreciseInhale Platform. Gerde P (Institute of Environmental Medicine, Karolinska Intitutet), Nowenwik M, (Inhalation Sciences Sweden AB), Sjöberg CO (Flexura AB, Upplands Väsby, Sweden) Selg E (Inhalation Sciences Sweden AB) Journal of Aerosol Medicine and Pulmonary Drug Delivery, Volume 32, October 2019.

  • Effect of Particle Deposition Density of Dry Powders on the Results Produced by an In Vitro Test System Simulating Dissolution- and Absorption Rates in the Lungs. Maria Malmlöf (ISAB), Mattias Nowenwik (ISAB), Kristof Meelich (pharm-analyt Labor GmbH, Baden, Austria),  Iwona Rådberg (ISAB), Ewa Selg (ISAB), John Burns (Circassia, UK), Hermann Mascher (pharm-analyt Labor GmbH, Baden, Austria), Per Gerde (ISAB / Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden). European Journal of Pharmaceutics & Biopharmaceutics, March 2019. 

  • Use of PBPK modelling to evaluate the performance of DissolvIt, a biorelevant dissolution assay for orally inhaled drug productsMireille HassounMaria MalmlofOtto ScheibelhoferAbhinav KumarSukhi BansalEwa SelgMattias NowenwikPer GerdeSnezana RadivojevAmrit PaudelSumit Arora, and Ben Forbes (King’s College London). Molecular Pharmaceutics,  Copyright © 2019 American Chemical Society. 

  • Biorelevant Dissolution Testing of Orally Inhaled Drugs: Adding a Newly Designed Pre-Separator to PreciseInhale. Beatriz Noriega, Eunice Costa (Hovione FarmaCiencia SA, Lisbon, Portugal), M. Luisa Corvo (iMed. ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Portugal), Maria Malmlöf, Per Gerde (Inhalation ScienceBNoriega_Hovione_PS_RDD2018 (1)s, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Sweden). 2018.  

  • A Comparison of DissolvIt Dissolution Profiles of Particles Deposited with a
    New Generation Impactor or with a PreciseInhale Aerosol Generator, Maria Malmlöf, P.Gerde (Karolinska Institutet, Sweden, Inhalation Sciences, Sweden), B.Noriega (Hovione FarmaCiencia SA, iMed. Univ’ Lisboa, Portugal) M. Nowenwik (Inhalation Sciences),  M.L.Corvo (Hovione FarmaCiencia SA), E. Costa (Univ’ Lisboa, Portugal) (RDD 2018)

  • A novel method for studying airway hyperresponsiveness in vivo using the PreciseInhale system for delivery of dry powder aerosols. A. J. Lexmond (Institute of Pharmaceutical Science, Kings College London, Sackler Institute of Pulmonary Pharmacology, KCL, Dept of Pharmaceutical Technology & Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands), S.Keir , C.P.Page (Institute of Pharmaceutical Science, KCL, London, Sackler Institute of Pulmonary Pharmacology, KCL), W. Terakosolphan, B. Forbes (Institute of Pharmaceutical Science, KCL, London, UK.) 2018.

  • Evaluating Impact of Inhaled Particle Size on PK Profile of AZD1 Using The PreciseInhale. Authors: Steven Oag, Caroline Karlsson, Per Åberg (AstraZeneca Drug Safety Metabolism), Anders Lundqvist, Ann Aurell Homberg (AstraZeneca RIA DMPK), Per Gerde, Carl Olof Sjöberg (ISAB). AIT Conference poster 2017.

  • Characterisation of aerosols from solution-based pressurised metered dose inhalers (pMDIs) when delivered by PreciseInhale®. Wachirun Terakosolphan (Institute of Pharmaceutical Science, King’s College London, UK), Maria Malmlöf (ISAB, Sweden), David Lewis (Chiesi Limited, Chippenham, UK), Ben Forbes (Institute of Pharmaceutical Science, King’s College London, UK). DDL poster 2017.

  • Aerosolizing PulmoSolTM and PulmoSphereTM with the PreciseInhale® system. Nowenwik, M (ISAB, Sweden), Malmlöf, M (ISAB, Sweden), Kadrichu, N (Novartis USA), Gerde, P (ISAB, KI Institute of Environmental Medicine, Sweden). ISAM conference poster, 2017.

  • Effect of Compressed Air Pressure on Particle Size Distribution During Aerosol Generation with Ultrafine TiO2.  Maria Malmlöf (ISAB), Mattias Nowenwik (ISAB), Per Gerde (ISAB, KI Institute of Environmental Medicine), DDL poster 2017.

  • Comparison of dissolution/absorption profiles of CuO and Cu nanoparticles by using the in vitro dissolution ranking tool DissolvIt®. Authors: Malmlöf,  Nowenwik, M (ISAB), Gerde, P (ISAB and KI Institute of Environmental Medicine), Karlsson, H. L. (KI Institute of Environmental Medicine, Sweden). Poster SOT 2017.

  • Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology. Alessandro Fioni, Chiesi Farmaceutici S.p.A., Italy. Ewa Selg, ISAB, Sweden. Valentina Cenacchi, Chiesi . Fernando Acevedo, ISAB, Giandomenico Brogin, Chiesi. Per Gerde, KI Institute of Environmental Medicine, ISAB, Paola Puccini, Chiesi. (2017)

  • DissolvIt: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs. Gerde P, Malmlöf M, Havsborn L, Sjöberg CO, Ewing P, Eirefelt S, Ekelund K. Inhalation Sciences Sweden AB, Institute of Environmental Medicine, Karolinska Institutet , Flexura AB , Astra Zeneca Ltd. (2017).

  • Development of Combining of Human Bronchial Mucosa Models with XposeALI® for Exposure of Air Pollution Nanoparticles Ji J, Hedelin A, Malmlöf M, Kessler V, Seisenbaeva G, Gerde P, et al. (2017)

  • Effect of using bio-relevant media in the DissolvIt ® system to measure dissolution of fluticasone propionate from Flixotide 50 µg Evohaler, joint poster King’s College London, ISAB. Authors: Mireille Hassoun, Maria Malmlöf, Abhinav Kumar, Sukhi Bansal, Mattias Nowenwik, Per Gerde, Mark Parry, Ben Forbes. Poster: DDL27, 2016.

  • In Vitro – Ex Vivo Correlation of Fluticasone Propionate Pharmacokinetic Profiles. Maria Börjel, Ewa Selg and Per Gerde (per.gerde@ki.se): Inhalation Sciences Sweden AB and PostInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Poster: DDL 2015

  • Inhalation Pharmacokinetics of a Respirable Formulation of a Selective PDE4 Inhibitor, CHF6001, in Three Exposure Models: Isolated Perfused Lung, Intratracheally Intubated, and Nose-Only Exposed Rat. Ewa Selg, Per Gerde, Fernando Acevedo, Inhalation Sciences Sweden AB, Stockholm, Sweden, Alessandro Fioni, Valentina Cenacchi, Giandomenico Brogin and Paola Puccini, Chiesi Farmaceutici, Preclinical DMPK, Parma, Italy.

    Poster: RDD 2015

  • A Spray Dryer Method for the Micronization of Small Amounts of Substance in High Yield for Aerosol Generation. Fernando Acevedo and Per Gerde, Inhalation Sciences Sweden AB, Stockholm, Sweden, and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

     

    Poster: Society of Toxicologists, March 2014

  • The DissolvIt: An In Vitro Evaluation of the Dissolution and Absorption of Three Inhaled Dry Powder Drugs in the Lung. Maria Börjel, Robyn C. Sadler, Per Gerde, Inhalation Sciences Sweden AB, Sweden, Glaxo Smith Klein, Hertfordshire UK and Karolinska Institutet, Stockholm, Sweden.

     

    Poster: Respiratory Drug Delivery to the Lungs conference, May 2014

  • Exposure of the Tracheally Intubated Rat to Aerosolized Lunar Dust Surrogate JSC1A-vf Ewa Selg, Fernando Acevedo, Bo Blomgren, G. Kim Prisk, Per Gerde, Inhalation Sciences Sweden AB, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden, Departments of Medicine and Radiology, UCSD, La Jolla, USA, Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

     

    Poster: Planetary and Space Science, 2012

  • Dry Powder Inhalation Exposures of the Endotracheally Intubated Rat Lung, Ex Vivo and In Vivo: The Pulmonary Pharmacokinetics of Fluticasone Furoate Selg, E, et al.

     

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012

  • Challenges in inhaled product development and opportunities for open innovation. Forbes, B., et al.,

     

    Adv Drug Deliv Rev, 2011. 63(1-2): p. 69-87.

  • Vasoconstriction after inhalation of budesonide: A study in the isolated and
    perfused rat lung.
    Ewing, P., et al.,

     

    Pulm Pharmacol Ther, 2010. 23: p. 9-14.

  • Delivering Horseradish Peroxidase as a Respirable Powder to the Isolated, Perfused and Ventilated Lung of the Rat: The Pulmonary Disposition of an Inhaled Model Selg, E., et al.,

     

    Biopharmaceutical. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010. 23(5): p. 273-284.

  • Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. Ewing, P., et al.,

     

    J Aerosol Med Pulm Drug Deliv, 2008. 21(2): p. 169-80.

  • Site-Specific, Dose-Dependent Transitional Analysis of Toxicologic Mechanisms: The Interplay of Local Metabolic and Physicochemical Saturation. Moss, O.R.,

     

    Toxicol. Sci., 2006. 91(2): p. 311312.

  • Increasing Exposure Levels Cause an Abrupt Change in the Absorption and Metabolism of Acutely Inhaled Benzo(a)pyrene in the Isolated, Ventilated, and Perfused Lung of the Rat. Ewing, P., et al.,

     

    Toxicol. Sci., 2006. 91(2): p. 332-340.

  • A novel method to aerosolize powder for short inhalation exposures at high concentrations: Isolated rat lungs exposed to respirable diesel soot Gerde, P., et al.,

     

    Inhalation Toxicology, 2004. 16(1): p. 45-52.

  • The rapid alveolar absorption of diesel-soot adsorbed benzo(a)pyreneBioavailability, metabolism, and dosimetry of an inhaled carcinogen. Gerde, P., et al.,

     

    Carcinogenesis, 2001. 22(5):